A joint FDA advisory panel on Tuesday recommended approval of Avedro’s combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking. The recommendation is the last step before the FDA renders a decision on March 29.
The FDA’s Dermatolog…

Actavis Plc started selling bonds in what may the biggest corporate debt deal in two years to finance its purchase of Botox-maker Allergan Inc. The drug company will issue the securities as soon as Tu…

Oraya Therapeutics announced that the Oraya IRay Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from pri…

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by in…

Michael Monteferrante, President and CEO of Envision, has been elected to the board of directors of the National Association for the Employment of People Who Are Blind (NAEPB). Monteferrante was also …

Clearside Biomedical announced the enrollment of the first patient in a phase 2, randomized, controlled, masked, multicenter clinical trial for the treatment of macular edema associated with retinal v…

Ohr Pharmaceutical announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting, which took place February 25-28, in Scottsdale, Arizona. The…

Eyegate Pharmaceuticals announced the appointment of Michael B. Raizman, MD, as the Consulting Chief Medical Officer. Dr. Raizman began working with the company as a consultant in the fourth quarter o…

Alcon presented results from its second phase 2 clinical study of RTH258 during the 38th Annual Macula Society Meeting in Scottsdale, Arizona. The study evaluated the efficacy and safety of the compou…

Nikon Corp. has agreed to acquire retinal imaging firm Optos for $400 million (259.3 million pounds) in cash, the companies announced Friday. Under terms of the agreement, Nikon will pay 340 pence a s…

Ocata Therapeutics, a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, announced that it has received notice that the NASDAQ Listing Qualifications Department h…